| Title |
Spotlight on ixazomib: potential in the treatment of multiple myeloma
|
|---|---|
| Published in |
Drug Design, Development and Therapy, January 2016
|
| DOI | 10.2147/dddt.s93602 |
| Pubmed ID | |
| Authors |
Barbara Muz, Rachel Nicole Ghazarian, Monica Ou, Micah John Luderer, Hubert Daniel Kusdono, Abdel Kareem Azab |
| Abstract |
Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the first oral PI approved by US Food and Drug Administration. This review discusses the biochemical properties, mechanisms of action, preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration approval of ixazomib. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 20% |
| India | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Scientists | 1 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 121 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 26 | 21% |
| Student > Ph. D. Student | 14 | 12% |
| Student > Master | 13 | 11% |
| Other | 12 | 10% |
| Researcher | 10 | 8% |
| Other | 20 | 17% |
| Unknown | 26 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 23% |
| Chemistry | 19 | 16% |
| Biochemistry, Genetics and Molecular Biology | 17 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 8% |
| Agricultural and Biological Sciences | 9 | 7% |
| Other | 11 | 9% |
| Unknown | 27 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2021.
All research outputs
#3,152,496
of 25,806,080 outputs
Outputs from Drug Design, Development and Therapy
#171
of 2,283 outputs
Outputs of similar age
#50,119
of 402,072 outputs
Outputs of similar age from Drug Design, Development and Therapy
#5
of 81 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 402,072 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.